
CLAIMS


1. Use of an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt of the foregoing, in the manufacture of a medicament for ameliorating or treating a viral infection caused by a virus selected from a henipavirus, a morbillivirus, a respirovirus, a rubulavirus and a metapneumovirus, wherein the compound of Formula (I), has the structure:



(I)

wherein:

B^{1A} is elected from the group consisting of:



and ;

wherein:

R^{A2} is selected from the group consisting of hydrogen, halogen and NHR^{J2}, wherein R^{J2} is hydrogen;

R^{B2} is halogen or NHR^{W2}, wherein R^{W2} is hydrogen;

R^{C2} is hydrogen or NHR^{O2}, wherein R^{O2} is hydrogen;

R^{D2} is selected from the group consisting of hydrogen, halogen and an unsubstituted C_{1-6} alkyl;

R^{E2} is selected from the group consisting of hydrogen, hydroxy and an unsubstituted C_{1-6} alkyl;




R^{F2} is selected from the group consisting of hydrogen, halogen, and an unsubstituted C_{1-6}alkyl;

Y^2 is N;

Y^3 is N or CR^{I2}, wherein R^{I2} is hydrogen;

R^{G2} is an unsubstituted C_{1-6} alkyl; and

R^{H2} is hydrogen or NHR^{T2}, wherein R^{T2} is hydrogen;

R^{1A} is selected from the group consisting of hydrogen, $-C(=O)R^{39A}$, an optionally substituted O-linked α–amino acid,  ,  and  ;



the dashed line (------) is absent;


R^{2A} is selected from the group consisting of an unsubstituted C_{1-6} alkyl, a halogen substituted C_{1-6} alkyl, a hydroxy substituted C_{1-6} alkyl, an alkoxy substituted C_{1-6} alkyl, a sulfenyl substituted C_{1-6} alkyl, an unsubstituted C_{2-6} alkenyl, an unsubstituted C_{2-6} alkynyl, an unsubstituted C_{3-6} cycloalkyl, an unsubstituted $-O-C_{1-6}$ alkyl and cyano;


R^{3A} is selected from the group consisting of OH, $-OC(=O)R^{"A}$ and an O-linked α-amino acid, wherein the O-linked α-amino acid is selected from the group consisting of O-linked alanine, O-linked asparagine, O-linked aspartate, O-linked cysteine, O-linked glutamate, O-linked glutamine, O-linked glycine, O-linked proline, O-linked serine, O-linked tyrosine, O-linked arginine, O-linked histidine, O-linked isoleucine, O-linked leucine, O-linked lysine, O-linked methionine, O-linked phenylalanine, O-linked threonine, O-linked tryptophan and O-linked valine;

R^{4A} is a halogen;

R^{5A} is hydrogen or halogen,


R^{6A}, R^{7A} and R^{8A} are independently selected from the group consisting of absent, hydrogen, an optionally substituted phenyl, an optionally substituted naphthyl,  and  ; or

R^{6A} is  and R^{7A} is absent or hydrogen; or



one of R^{6A} and R^{7A} is and the other of R^{6A} and R^{7A} is OH or O^-;

R^{6A} and R^{7A} are taken together with the oxygens connected to R^{6A} and R^{7A} to form



;

R^{9A} is an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine, or an unsubstituted C_{1-6} alkyl ester, an optionally substituted C_{3-6} cycloalkyl ester, an optionally substituted C_6 aryl ester, an optionally substituted C_{10} aryl ester or an optionally substituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine;

R^{10A} and R^{11A} are independently an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-

linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine, or an unsubstituted C_{1-6} alkyl ester, an optionally substituted C_{3-6} cycloalkyl ester, an optionally substituted C_6 aryl ester, an optionally substituted C_{10} aryl ester or an optionally substituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine;

R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen;

R^{22A} and R^{23A} are independently hydrogen or an unsubstituted C_{1-4} alkyl;


R^{24A} is selected from the group consisting of hydrogen, an unsubstituted C_{1-24} alkyl and an unsubstituted –O–C_{1-24} alkyl;

R^{25A} is hydrogen or an unsubstituted C_{1-24} alkyl;

$R^{"A}$ and R^{39A} are independently an unsubstituted C_{1-24}-alkyl;

m and n are independently 0 or 1;

Z^{1A}, Z^{2A}, Z^{3A} and Z^{4A} are O; and



provided that when R^{1A} is wherein R^{8A} is phenyl optionally para-substituted with a halogen or methyl and R^{9A} is methyl ester, ethyl ester, isopropyl ester, n-butyl ester, benzyl ester or phenyl ester of an α–amino acid selected from the group consisting of glycine, alanine, valine, leucine, phenylalanine, tryptophan, methionine and proline; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro or hydrogen; and B^{1A} is an unsubstituted uracil; then R^{2A} cannot be $-OCH_3$;

provided that when R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be allenyl; and

provided that when R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be ethynyl; and

a heteroaryl is a 4 to 14 atoms monocyclic or multicyclic aromatic ring system that contains one or more heteroatoms selected from nitrogen, oxygen and sulfur; and

when a substituent is indicated as optionally substituted. the substituent may be substituted with one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, alkoxy, aryloxy, acyl, mercapto, alkylthio, arylthio, cyano, halogen, haloalkyl, haloalkoxy, an amino, a mono-substituted amino group and a di-substituted amino group;

2. The use of Claim 1, wherein the virus is selected from the group consisting of a henipavirus, a morbillivirus and a rubulavirus.

3. The use of Claim 2, wherein the henipavirus is a nipahvirus; wherein the morbillivirus is the measles virus; and/or wherein the rubulavirus is the mumps virus.

4. The use of Claim 1, wherein the virus is a respirovirus.

5. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 1.



6. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 3.

7. The use of Claim 1, wherein the virus is a rubulavirus.


8. The use of Claim 7, wherein the rubulavirus is selected from the group consisting of human parainfluenza virus 2 and human parainfluenza virus 4.


9. The use of Claim 1, wherein the virus is a metapneumovirus.

10. The use of Claim 9, wherein the metaphenumovirus is human metapneumovirus.

11. The use of any one of Claims 1-10, wherein R^{1A} is  , ,  or .

12. The use of Claim 11, wherein R^{6A} and R^{7A} are both hydrogen or absent.

13. The use of Claim 11, wherein R^{6A} and R^{7A} are both  .

14. The use of Claim 11, wherein R^{6A} and R^{7A} are both  ;.

15. The use of Claim 11, wherein R^{8A} is an optionally substituted phenyl; and R^{9A} is an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine, or an unsubstituted C_{1-6} alkyl ester, an optionally substituted C_{3-6} cycloalkyl ester, an optionally substituted C_6 aryl ester, an optionally substituted C_{10} aryl ester or an optionally substituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine.

16. The use of Claim 11, wherein R^{9A} is selected from the group consisting of N-linked alanine, N-linked glycine, N-linked leucine, N-linked valine, N-linked alanine isopropyl ester, N-linked alanine cyclohexyl ester, N-linked alanine neopentyl ester, N-linked valine isopropyl ester and N-linked leucine isopropyl ester.


17. The use of Claim 16, wherein R^{9A} is selected from the group consisting of N-linked alanine, N-linked alanine isopropyl ester, N-linked alanine cyclohexyl ester and N-linked alanine neopentyl ester.

18. The use of Claim 11, wherein R^{10A} and R^{11A} are independently an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine, or an unsubstituted C_{1-6} alkyl ester, an optionally substituted C_{3-6} cycloalkyl ester, an optionally substituted C_6 aryl ester, an optionally substituted C_{10} aryl ester or an optionally substituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked

lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine

19. The use of Claim 18, wherein R^{10A} and R^{11A} are independently selected from the group consisting of N-linked alanine, N-linked glycine, N-linked leucine, N-linked valine, N-linked alanine isopropyl ester, N-linked alanine cyclohexyl ester, N-linked alanine neopentyl ester, N-linked valine isopropyl ester and N-linked leucine isopropyl ester.

20. The use of Claim 18, wherein R^{10A} and R^{11A} are independently selected from the group consisting of N-linked alanine, N-linked alanine isopropyl ester, N-linked alanine cyclohexyl ester and N-linked alanine neopentyl ester.



21. The use of Claim 11, wherein R^{6A} is , m; R^{7A} is absent or hydrogen; m is 0; and R^{12A} and R^{13A} are independently absent or hydrogen.

22. The use of Claim 11, wherein m is 1; and R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen.

23. The use of any one of Claims 1-10, wherein R^{1A} is H.







24. The use of any one of Claims 1-10, wherein R^{1A} is $-C(=O)R^{39A}$.




25. The use of Claim 24, wherein R^{39A} is an unsubstituted C_{1-12} alkyl.



26. The use of any one of Claims 1-10, wherein R^{1A} is an optionally substituted O-linked α–amino acid selected from the group consisting of O-linked alanine, O-linked glycine, O-linked leucine and O-linked valine.


27. The use of Claim 26, wherein R^{1A} is O-linked alanine or O-linked valine.

28. The use of any one of Claims 1-27, wherein B^{1A} is selected from the group consisting of:





and

and

, wherein R^{G2} is an unsubstituted C_{1-6} alkyl; and R^{H2} is hydrogen or NHR^{T2}, wherein R^{T2} is hydrogen.

29. The use of Claim 28, wherein B^{1A} is

,

or

, wherein R^{G2} is an unsubstituted C_{1-6} alkyl; and R^{H2} is hydrogen or NHR^{T2}, wherein R^{T2} is hydrogen.

30. The use of Claim 28, wherein B^{1A} is

or


31. The use of Claim 28, wherein B^{1A} is

.

32. The use of any one of Claims 1-31, wherein R^{2A} is a halogen substituted C_{1-6} alkyl or a sulfenyl substituted C_{1-6} alkyl, and R^{3A} is selected from the group consisting of OH, $-OC(=O)R^{"A}$ and an O-linked α–amino acid selected from the group consisting of O-linked alanine, O-linked glycine, O-linked leucine and O-linked valine.

33. The use of any one of Claims 1-31, wherein R^{2A} is an unsubstituted C_{1-6} alkyl.

34. The use of Claim 33, wherein R^{2A} is a halogen substituted C_{1-6} alkyl.

35. The use of one of Claims 1-31, wherein R^{2A} is an unsubstituted C_{2-6} alkenyl, an unsubstituted C_{2-6} alkynyl, an unsubstituted C_{3-6} cycloalkyl, an unsubstituted $-O-C_{1-6}$ alkyl or cyano.

36. The use of any one of Claims 1-35, wherein R^{3A} is OH.

37. The use of any one of Claims 1-35, wherein R^{3A} is $-OC(=O)R^{"A}$, wherein $R^{"A}$ is an unsubstituted C_{1-8} alkyl.


38. The use of any one of Claims 1-35, wherein R^{3A} is O-linked alanine or O-linked valine.


39. The use of any one of Claims 1-38, wherein R^{5A} is hydrogen.




40. The use of any one of Claims 1-38, wherein R^{5A} is halogen.

41. The use of any one of Claims 1-40, wherein R^{4A} is fluoro.














42. The use of any one of Claims 1-10, wherein the compound of Formula (I) is selected from the group consisting of:




































and

, or a pharmaceutically acceptable salt of the foregoing.

43. The use of any one of Claims 1-10, wherein the compound of Formula (I) is selected from the group consisting of:



,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




,




,




,




,




,




,







,




,




,




,














,



,















,










,

,

,

,

,

,

,

,

,

,

,

,











,










,



,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of the foregoing.


44. The use of any one of Claims 1-10, wherein the compound of Formula (I) is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,



,

,

,

,
,

,

,

,

,

,




,




,




,




,













,




,



,



,

,

,

,

,

and

, or a pharmaceutically acceptable salt of the foregoing.

45. The use of any one of Claims 1-10, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

46. The use of Claim 45, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

47. The use of Claim 45, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.


48. The use of Claim 45, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

CLAIMS







1. Use of an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt of the foregoing, in the manufacture of a medicament for ameliorating or treating a viral infection caused by a virus selected from a henipavirus, a morbillivirus, a respirovirus, a rubulavirus and a metapneumovirus, wherein the compound of Formula (I), has the structure:



(I)

wherein:

B^{1A} is selected from the group consisting of:


,

,

,

,

and

;

wherein:

R^{A2} is selected from the group consisting of hydrogen, halogen and NHR^{J2}, wherein R^{J2} is hydrogen;

R^{B2} is halogen or NHR^{W2}, wherein R^{W2} is hydrogen;

R^{C2} is hydrogen or NHR^{O2}, wherein R^{O2} is hydrogen;

R^{D2} is selected from the group consisting of hydrogen, halogen and an unsubstituted C_{1-6} alkyl;

R^{E2} is selected from the group consisting of hydrogen, hydroxy and an unsubstituted C_{1-6} alkyl;



R^{F2} is selected from the group consisting of hydrogen, halogen and an unsubstituted C_{1-6}alkyl;

Y^2 is N;

Y^3 is N or CR^{I2}, wherein R^{I2} is hydrogen;

R^{G2} is an unsubstituted C_{1-6} alkyl; and

R^{H2} is hydrogen or NHR^{T2}, wherein R^{T2} is hydrogen;

R^{1A} is selected from the group consisting of hydrogen, $-C(=O)R^{39A}$, an unsubstituted O-linked α–amino acid,  and  ;



the dashed line (------) is absent;


R^{2A} is selected from the group consisting of an unsubstituted C_{1-6} alkyl, a halogen substituted C_{1-6} alkyl, a hydroxy substituted C_{1-6} alkyl, an alkoxy substituted C_{1-6} alkyl, a sulfenyl substituted C_{1-6} alkyl, an unsubstituted C_{2-6} alkenyl, an unsubstituted C_{2-6} alkynyl, an unsubstituted C_{3-6} cycloalkyl, an unsubstituted $-O-C_{1-6}$ alkyl and cyano;


R^{3A} is selected from the group consisting of OH, $-OC(=O)R''^{A}$ and an O-linked α–amino acid, wherein the O-linked α-amino acid is selected from the group consisting of O-linked alanine, O-linked glycine, O-linked tyrosine, O-linked isoleucine, O-linked leucine, O-linked lysine, O-linked methionine, O-linked phenylalanine, O-linked tryptophan and O-linked valine;


R^{4A} is halogen;

R^{5A} is hydrogen or halogen,

R^{6A}, R^{7A} and R^{8A} are independently selected from the group consisting of absent, hydrogen, an unsubstituted phenyl, an unsubstituted naphthyl,  and  ; or

R^{6A} is  and R^{7A} is absent or hydrogen; or

one of R^{6A} and R^{7A} is  and the other of R^{6A} and R^{7A} is OH or O^-;

R^{6A} and R^{7A} are taken together with the oxygens connected to R^{6A} and R^{7A} to form  ;

R^{9A} is an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked glycine, N-linked tyrosine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked tryptophan and N-linked valine, or an unsubstituted C_{1-6} alkyl ester, an unsubstituted C_{3-6} cycloalkyl ester, an unsubstituted C_6 aryl ester, an unsubstituted C_{10} aryl ester or an unsubstituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked glycine, N-linked tyrosine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked tryptophan and N-linked valine;

R^{10A} and R^{11A} are independently an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked glycine, N-linked tyrosine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked tryptophan and N-linked valine, or an unsubstituted C_{1-6} alkyl ester, an unsubstituted C_{3-6} cycloalkyl ester, an unsubstituted C_6 aryl ester, an unsubstituted C_{10} aryl ester or an unsubstituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked glycine, N-linked tyrosine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked tryptophan and N-linked valine;

R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen;

R^{22A} and R^{23A} are independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{24A} is selected from the group consisting of hydrogen, an unsubstituted C_{1-24} alkyl and an unsubstituted –O–C_{1-24} alkyl;


R^{25A} is hydrogen or an unsubstituted C_{1-24} alkyl;

$R^{"A}$ is an unsubstituted C_{1-24}-alkyl;

R^{39A} is an unsubstituted C_{1-12} alkyl;

m is 0 or 1;

Z^{1A}, Z^{2A}, Z^{3A} and Z^{4A} are O; and



provided that when R^{1A} is wherein R^{8A} is phenyl and R^{9A} is methyl ester, ethyl ester, isopropyl ester, n-butyl ester, benzyl ester or phenyl ester of an α–amino acid selected from the group consisting of glycine, alanine, valine, leucine, phenylalanine, tryptophan and methionine; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro or hydrogen; and B^{1A} is an unsubstituted uracil; then R^{2A} cannot be $-OCH_3$;

provided that when R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be allenyl; and

provided that when R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be ethynyl.

2. The use of Claim 1, wherein the virus is selected from the group consisting of a henipavirus, a morbillivirus and a rubulavirus.

3. The use of Claim 2, wherein the henipavirus is a nipahvirus; wherein the morbillivirus is the measles virus; and/or wherein the rubulavirus is the mumps virus.

4. The use of Claim 1, wherein the virus is a respirovirus.

5. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 1.



6. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 3.

7. The use of Claim 1, wherein the virus is a rubulavirus.


8. The use of Claim 7, wherein the rubulavirus is selected from the group consisting of human parainfluenza virus 2 and human parainfluenza virus 4.


9. The use of Claim 1, wherein the virus is a metapneumovirus.

10. The use of Claim 9, wherein the metaphenumovirus is human metapneumovirus.

11. The use of any one of Claims 1-10, wherein R^{1A} is  or  .

12. The use of Claim 11, wherein R^{6A} and R^{7A} are both hydrogen or absent.

13. The use of Claim 11, wherein R^{6A} and R^{7A} are both  .

14. The use of Claim 11, wherein R^{6A} and R^{7A} are both  ;.

15. The use of Claim 11, wherein R^{8A} is an unsubstituted phenyl; and R^{9A} is an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked glycine, N-linked tyrosine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked tryptophan and N-linked valine, or an unsubstituted C_{1-6} alkyl ester, an unsubstituted C_{3-6} cycloalkyl ester, an unsubstituted C_6 aryl ester, an unsubstituted C_{10} aryl ester or an unsubstituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked glycine, N-linked tyrosine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked tryptophan and N-linked valine.

16. The use of Claim 11, wherein R^{9A} is selected from the group consisting of N-linked alanine, N-linked glycine, N-linked leucine, N-linked valine, N-linked alanine isopropyl ester, N-linked alanine cyclohexyl ester, N-linked alanine neopentyl ester, N-linked valine isopropyl ester and N-linked leucine isopropyl ester.



17. The use of Claim 16, wherein R^{9A} is selected from the group consisting of N-linked alanine, N-linked alanine isopropyl ester, N-linked alanine cyclohexyl ester and N-linked alanine neopentyl ester.



18. The use of Claim 11, wherein R^{10A} and R^{11A} are independently an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked glycine, N-linked tyrosine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked tryptophan and N-linked valine, or an unsubstituted C_{1-6} alkyl ester, an unsubstituted C_{3-6}

cycloalkyl ester, an unsubstituted C_6 aryl ester, an unsubstituted C_{10} aryl ester or an unsubstituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked glycine, N-linked tyrosine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked tryptophan and N-linked valine.

19. The use of Claim 18, wherein R^{10A} and R^{11A} are independently selected from the group consisting of N-linked alanine, N-linked glycine, N-linked leucine, N-linked valine, N-linked alanine isopropyl ester, N-linked alanine cyclohexyl ester, N-linked alanine neopentyl ester, N-linked valine isopropyl ester and N-linked leucine isopropyl ester.

20. The use of Claim 18, wherein R^{10A} and R^{11A} are independently selected from the group consisting of N-linked alanine, N-linked alanine isopropyl ester, N-linked alanine cyclohexyl ester and N-linked alanine neopentyl ester.

21. The use of Claim 11, wherein R^{1A} is  ; R^{6A} is  ; R^{7A} is absent or hydrogen; m is 0; and R^{12A} and R^{13A} are independently absent or hydrogen.

22. The use of Claim 11, wherein R^{1A} is  ; R^{6A} is  ; m is 1; and R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen.

23. The use of any one of Claims 1-10, wherein R^{1A} is H.







24. The use of any one of Claims 1-10, wherein R^{1A} is $-C(=O)R^{39A}$.




25. The use of Claim 24, wherein R^{39A} is an unsubstituted C_{1-3} alkyl.



26. The use of any one of Claims 1-10, wherein R^{1A} is an unsubstituted O-linked α–amino acid selected from the group consisting of O-linked alanine, O-linked glycine, O-linked leucine and O-linked valine.


27. The use of Claim 26, wherein R^{1A} is O-linked alanine or O-linked valine.

28. The use of any one of Claims 1-27, wherein B^{1A} is selected from the group consisting of:


,

,

,

and

and

, wherein R^{G2} is an unsubstituted C_{1-6} alkyl; and R^{H2} is hydrogen or NHR^{T2}, wherein R^{T2} is hydrogen.

29. The use of Claim 28, wherein B^{1A} is

,

or

, wherein R^{G2} is an unsubstituted C_{1-6} alkyl; and R^{H2} is hydrogen or NHR^{T2}, wherein R^{T2} is hydrogen.

30. The use of Claim 28, wherein B^{1A} is

or


31. The use of Claim 28, wherein B^{1A} is  .

32. The use of any one of Claims 1-31, wherein R^{2A} is a halogen substituted C_{1-6} alkyl or a sulfenyl substituted C_{1-6} alkyl, and R^{3A} is selected from the group consisting of OH, $-OC(=O)R^{"A}$ and an O-linked α–amino acid selected from the group consisting of O-linked alanine, O-linked glycine, O-linked leucine and O-linked valine.

33. The use of any one of Claims 1-31, wherein R^{2A} is an unsubstituted C_{1-6} alkyl.

34. The use of Claim 33, wherein R^{2A} is a halogen substituted C_{1-6} alkyl.

35. The use of one of Claims 1-31, wherein R^{2A} is an unsubstituted C_{2-6} alkenyl, an unsubstituted C_{2-6} alkynyl, an unsubstituted C_{3-6} cycloalkyl, an unsubstituted $-O-C_{1-6}$ alkyl or cyano.

36. The use of any one of Claims 1-35, wherein R^{3A} is OH.

37. The use of any one of Claims 1-35, wherein R^{3A} is $-OC(=O)R^{"A}$, wherein $R^{"A}$ is an unsubstituted C_{1-8} alkyl.


38. The use of any one of Claims 1-35, wherein R^{3A} is O-linked alanine or O-linked valine.


39. The use of any one of Claims 1-38, wherein R^{5A} is hydrogen.




40. The use of any one of Claims 1-38, wherein R^{5A} is halogen.

41. The use of any one of Claims 1-40, wherein R^{4A} is fluoro.














42. The use of any one of Claims 1-10, wherein the compound of Formula (I) is selected from the group consisting of:



































and

, or a pharmaceutically acceptable salt of any of the foregoing.















43. The use of any one of Claims 1-5, wherein the compound of Formula (I) is selected from the group consisting of:














,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,

,

,

,










,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,











,










,



,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.


44. The use of any one of Claims 1-10, wherein the compound of Formula (I) is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,



,

,

,

, ,

,

,

, .

,

,




,




,




,




,













,




,



,



,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.

45. The use of any one of Claims 1-10, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

46. The use of Claim 45, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

47. The use of Claim 45, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

48. The use of Claim 45, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

49. The use of Claim 45, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.